Straits Times Index
3,330.09 +11.64 (+0.35%) S&P 500
5,304.72 +36.88 (+0.70%) Dow
39,069.59 +4.29 (+0.01%) Nasdaq
16,920.79 +184.79 (+1.10%) Bitcoin USD
68,170.62 -415.81 (-0.61%) CMC Crypto 200
1,485.29 -11.17 (-0.75%)
Eli Lilly and Company (LLY.F)
| Previous close | 748.80 |
| Open | 745.60 |
| Bid | 745.10 x 30000 |
| Ask | 747.00 x 30000 |
| Day's range | 744.20 - 747.60 |
| 52-week range | 387.40 - 754.90 |
| Volume | |
| Avg. volume | 516 |
| Market cap | 709.572B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 118.70 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.79 (0.64%) |
| Ex-dividend date | 15 May 2024 |
| 1y target est | N/A |
- PR Newswire
Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines
Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion. This expansion will enhance Lilly's capacity to manufacture active pharmaceutical ingredients (API) for Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection so that more adults with chronic diseases like obesity and ty
- PR Newswire
Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a rearranged during transfection [RET] inhibitor), olomorasib (an investigational KRAS G12C inhibitor) and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.
- PR Newswire
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
In Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically significant and clinically meaningful improvements across multiple clinical and endoscopic endpoints at one year with mirikizumab compared to placebo. Data from this study – the first Phase 3 treat-through data reported for an IL23p19 antibody – will be presented at Digestive Disease Week® (DDW), held
